Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 107.70M P/E - EPS this Y 44.00% Ern Qtrly Grth -
Income -58.35M Forward P/E -2.11 EPS next Y 37.30% 50D Avg Chg -28.00%
Sales 1.78M PEG - EPS past 5Y - 200D Avg Chg -42.00%
Dividend N/A Price/Book 2.76 EPS next 5Y - 52W High Chg -71.00%
Recommedations 2.00 Quick Ratio 1.87 Shares Outstanding 71.52M 52W Low Chg 6.00%
Insider Own 19.06% ROA -63.48% Shares Float 34.45M Beta -0.11
Inst Own 26.00% ROE -219.18% Shares Shorted/Prior 444.13K/746.98K Price 3.40
Gross Margin -78.30% Profit Margin - Avg. Volume 497,835 Target Price 3.75
Oper. Margin -1,988.43% Earnings Date Nov 11 Volume 556,749 Change -2.02%
About Beyond Air, Inc.

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Beyond Air, Inc. News
11/14/24 Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/11/24 Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
11/11/24 Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/29/24 Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast
10/07/24 Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/02/24 Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks
09/28/24 Beyond Air to sell 40.39M shares at 51c in private placement
09/28/24 Beyond Air terminates loan, security agreements with Avenue Capital
09/27/24 Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed
09/27/24 Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital
09/27/24 Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
09/23/24 Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
08/08/24 Beyond Air First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
08/06/24 Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
07/31/24 Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia
07/23/24 Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6
07/16/24 Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024
06/24/24 Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
06/13/24 Beyond Air® Appoints David Webster as Chief Commercial Officer
06/03/24 Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)
XAIR Chatroom

User Image 45IQ Posted - 1 day ago

$XAIR in for another 20k at .49

User Image BMK00 Posted - 1 day ago

$SGMO Robert Carey also serves on the board of $XAIR, and has invested millions. Both will be multi-baggers with some serious legs in 2025 IMHO. GL!

User Image VernCapital Posted - 2 days ago

$XAIR

User Image Newb101 Posted - 3 days ago

$AEHL $BON $XAIR

User Image VernCapital Posted - 6 days ago

$XAIR seeing a wobble in all healthcare today - that said if someone could come in and shake the FDA up 🤷🏻‍♂️

User Image LiquidatingValue Posted - 6 days ago

$XAIR New positions in XAIR as of 2024-11-14 Lasry Marc 4,946,697 Soros Fund Management Llc 1,476,626

User Image Grumpy56 Posted - 6 days ago

$XAIR 13-F’s are out. Of current top 5, three are new, one sold 0.98% and Vanguard had no activity. Blackrock sold about 71%, and Adirl sold 76%, both still in top 10 institutions investors. Institutions increased ownership from 5.6M to 7.9M shares. Tutes own 21.6%. Data is per Nasdaq website.

User Image DarkOrb Posted - 1 week ago

$XAIR 😂 might need to use a log scale. On a shorter time frame, it does look like the selling might be exhausted. We'll see. Still could see some tax loss selling before the end of the year.

User Image VernCapital Posted - 1 week ago

$XAIR look how tight that range is now

User Image TomekW Posted - 1 week ago

$XAIR

User Image midnite_clyde Posted - 1 week ago

$XAIR Who's taking away Mallinckrodt's business. Velo is hiring night shift mfg??? "This reflects a decrease of 2.0% on a reported basis and 1.9% on a constant currency basis, primarily due to continued competition from alternative nitric oxide products on INOmax"

User Image midnite_clyde Posted - 1 week ago

$XAIR October corporate deck fills in the blanks Lisi misses.

User Image midnite_clyde Posted - 1 week ago

$XAIR Looks like VA not the biggest opportunity. Really not certain why Lisi emphasized this over other important facts (transport-ready units approval late 2024 or early 2025). Dilution and shelving revenue generators LungFit Pro and LungFit Go are real bummers but CE Mark and cardiac approval should get some momentum going. Lisi and Casey are smarter than me (I hope), so I'm hanging in here. Google AI shows this: "The VA (Veterans Affairs) does not have hospitals that directly deliver babies, but it does provide maternity care benefits for newborns: Maternity care The VA offers care for newborns for the first seven days after birth. VA has 170 VA Medical Centers

User Image JasonKruger Posted - 1 week ago

$XAIR Just based on previous patterns my guess is some of this movement is insider buying.

User Image VernCapital Posted - 1 week ago

$XAIR gap to fill at 46c but is the selling exhausted at this level? Seems to be holding

User Image Say_Whaaaat Posted - 1 week ago

$XAIR does anyone think they RS or delist and go private?

User Image VP_BagHolderInc Posted - 1 week ago

$XAIR

User Image VernCapital Posted - 1 week ago

$XAIR when you think it’s only down a few cents on earnings but then you also think ….

User Image jholzy Posted - 1 week ago

$XAIR - Ok so future looks slightly better but what about compliance of being back over $1.00. Anyone know what that has to be figured by?

User Image StocktwitsNews Posted - 1 week ago

Beyond Air Stock Slides After Q2 Earnings Beat, Retail’s Confiden. $XAIR https://stevents.onelink.me/wmCS/n3bzss6e

User Image VernCapital Posted - 1 week ago

$XAIR hanging on the 20ma .44c 50day is .40c Bottom of bolly band around .30c

User Image VernCapital Posted - 1 week ago

$XAIR I don’t know what previous CCO (Duncan Fatkin) was smoking when he said “I expect the quarters to be in the millions” in 2023. Clear disconnect between reality. Now we see what David Webster can do.

User Image 45IQ Posted - 1 week ago

@Tomppa I found this stock $XAIR through Carey @ $SGMO , been reading past news and rev guidance. You guys aren't a huge Lisi fan I can gather from that lmao. I think the call was certainly mixed but with a focus on new management for sales and partnerships. I do like that there isn't any shying away from acknowledging past fault in guidance. Cash into 2026 while they figure out different marketing strategies

User Image Tomppa Posted - 1 week ago

$XAIR maybe I add once more a good chunk before end of the year when others dump theirs for tax reasons to be prepared for CE approval and the sales improvements. One more time, I feel like a addict that can’t stop even if should 😅

User Image TimMccain Posted - 1 week ago

$XAIR time to buy another few thousand shares. Easy money

User Image slevin_kelevra Posted - 1 week ago

$XAIR every earning same story, share price plummet

User Image BobintheBuff Posted - 1 week ago

$XAIR fully expect some tax loss selling over the next month. How low will it go…

User Image VernCapital Posted - 1 week ago

$XAIR didn’t seem too bad of a call. I mean at this point our expectations are pretty low. Looks like margins will improve from March. Cost cutting improving now qtr on qtr. Signed contracts as of now on par with this reported quarter with 7 weeks left of the year to go. New CCO appears to be opening up some doors that prior CCO couldn’t. Still way off the once guided 4m revenue a month but CE mark and cardiac could be a game changer.

User Image DarkOrb Posted - 1 week ago

$XAIR They sort of addressed the lack of revenue on the call, but it sounded like the company is 2-3 quarters away from beating the revenue of a single Chick-fil-A location. I still don't understand why Carey has continued to dump so much money into this thing.

User Image StocktwitsNews Posted - 1 week ago

Beyond Air Stock Rises Ahead Of Earnings: Retail Bullish. $XAIR https://stevents.onelink.me/wmCS/wvq5gml3

Analyst Ratings
Piper Sandler Overweight Aug 7, 24
Piper Sandler Overweight Jun 25, 24
BTIG Neutral Jun 25, 24
Truist Securities Buy Apr 30, 24
Truist Securities Buy Nov 14, 23
Piper Sandler Overweight Jul 28, 23
Truist Securities Buy Jul 21, 23
Oppenheimer Outperform Jun 23, 23
BTIG Buy Jun 15, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Carey Robert Director Director Dec 18 Buy 1.635 1,200,000 1,962,000 2,374,454 12/19/23
Carey Robert Director Director Aug 18 Buy 2.7 88,664 239,393 975,160 08/22/23
Carey Robert Director Director Mar 29 Buy 6.38 20,000 127,600 886,496 03/30/23
Lee Yoori Director Director Mar 28 Buy 6.34 3,115 19,749 12,654 03/29/23
Carey Robert Director Director Nov 16 Buy 5.9 50,000 295,000 792,323 11/18/22
Gaul Michael A. Chief Operating Offi.. Chief Operating Officer Aug 22 Buy 9.42 2,000 18,840 64,150 08/22/22
Carey Robert Director Director Mar 24 Buy 6.62 26,185 173,345 547,323 03/28/22
Lisi Steven A. CEO and Chairman of.. CEO and Chairman of the Board Jan 12 Option 3.66 83,334 305,002 1,233,445 01/14/22
BENTSUR RON Director Director Nov 24 Sell 13.72 37,464 514,006 182,436 11/26/21